Loureirin A
Based on 6 publication(s) in Google Scholar
Loureirin A is a flavonoid extracted from Dragon's Blood, can inhibit Akt phosphorylation, and has antiplatelet activity.
연구목적의 판매만을 진행합니다. 환자를 대상으로 한 판매는 하지 않습니다.
- Purity: 99.96%
- CAS No.: 119425-89-7
- 화학식: C17H18O4
- 분자량:286.32
-
보관:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year
-
Biological Activity
-
Chemical Information
-
용액&용해도
- 순도&문서
- References
-
Help & FAQs
-
Kinase Inhibitor Library
HY-L009
-
PI3K/Akt/mTOR Compound Library
HY-L015
-
Stem Cell Signaling Compound Library
HY-L017
-
Natural Product Library
HY-L021
-
Autophagy Compound Library
HY-L029
-
Anti-Aging Compound Library
HY-L034
-
Differentiation Inducing Compound Library
HY-L038
-
Lipid Compound Library
HY-L043
-
Oxygen Sensing Compound Library
HY-L045
-
Anti-Cardiovascular Disease Compound Library
HY-L046
-
Medicine Food Homology Compound Library
HY-L055
-
Phenols Library
HY-L057
-
Glycolysis Compound Library
HY-L058
-
Cytoskeleton Compound Library
HY-L060
-
Glutamine Metabolism Compound Library
HY-L064
-
Traditional Chinese Medicine Active Compound Library
HY-L065
-
Anti-Breast Cancer Compound Library
HY-L074
-
Anti-Lung Cancer Compound Library
HY-L075
-
Anti-Pancreatic Cancer Compound Library
HY-L077
-
Anti-Blood Cancer Compound Library
HY-L079
-
Anti-Cancer Metabolism Compound Library
HY-L083
-
Anti-Obesity Compound Library
HY-L087
-
Angiogenesis-Related Compound Library
HY-L088
-
Glucose Metabolism Compound Library
HY-L092
-
Targeted Diversity Library
HY-L099
-
Anti-Liver Cancer Compound Library
HY-L101
-
Anti-Colorectal Cancer Compound Library
HY-L103
-
Plant-Sourced Natural Product Library
HY-L115
-
Human Metabolite Library
HY-L123
-
Anti-Prostate Cancer Compound Library
HY-L124
-
Anti-Pulmonary Fibrosis Compound Library
HY-L125
-
Cancer Stem Cells Compound Library
HY-L135
-
Coagulation and Anti-coagulation Compound Library
HY-L136
-
Pain-Related Compound Library
HY-L139
-
Serine/Threonine Kinase Inhibitor Library
HY-L164
-
Anti-Hematopathy Compound Library
HY-L171
-
Anti-Ovarian Cancer Compound Library
HY-L173
-
Bioactive Compound Library Max
HY-L181
-
MCE Bioactive Compound Library
HY-L001V
-
Natural Product Library Plus
HY-L021P
-
Natural Product and Natural Product-Like Compound Library
HY-L021M
-
Bioactive Compound Library
HY-L001
-
Anti-Gastric Cancer Compound Library
HY-L184
-
Anti-Fibrosis Compound Library
HY-L185
-
Tibetan Medicine Compound Library
HY-L191
-
PBCRBS Traditional Chinese Medicine Compound Library
HY-L193
-
Protein Kinase Compound Library
HY-L196
-
Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library
HY-L199
-
RO5 Drug-like Natural Product Library
HY-L200
-
Cell Proliferation Compound Library
HY-L201
-
High-Throughput Bioactive Compound Library
HY-L205
-
High-Throughput Natural Product Library
HY-L206
-
Mass Spectrometry Human Metabolite Library
HY-L215
-
Diarrhea-Related Traditional Chinese Medicine Active Compound Library
HY-L224
-
Posttranslational Modification Library
HY-L226
-
Mongolian Medicine Compound Library
HY-L238
-
Lactylation Compound Library
HY-L249
-
Mass Spectrometry Natural Product Library
HY-L262
Publications Citing Use of MedChemExpress (MCE) Loureirin A
More
Biological Activity
Akt[1]
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| A549 | IC50 |
89.5 μM
Compound: 10
|
Cytotoxicity against human A549 cells after 72 hrs by MTT assay
Cytotoxicity against human A549 cells after 72 hrs by MTT assay
|
[PMID: 19689125] |
| B16-BL6 | IC50 |
55.5 μM
Compound: 10
|
Cytotoxicity against mouse B16-BL6 cells after 72 hrs by MTT assay
Cytotoxicity against mouse B16-BL6 cells after 72 hrs by MTT assay
|
[PMID: 19689125] |
| HeLa | IC50 |
>100 μM
Compound: 10
|
Cytotoxicity against human HeLa cells after 72 hrs by MTT assay
Cytotoxicity against human HeLa cells after 72 hrs by MTT assay
|
[PMID: 19689125] |
| HT-1080 | IC50 |
>100 μM
Compound: 10
|
Cytotoxicity against human HT1080 cells after 72 hrs by MTT assay
Cytotoxicity against human HT1080 cells after 72 hrs by MTT assay
|
[PMID: 19689125] |
Loureirin A (50 μM, 100 μM) inhibits collagen-induced platelet ATP secretion and thrombin-stimulated P-selectin expression in a dose-dependent manner. Loureirin A also significantly impairs platelet spreading on immobilized fibrinogen. Loureirin A almost completely eliminates collagen-induced Akt phosphorylation at Ser473 at the dose of 100 μM, and has an additive inhibitory effect with the phosphoinositide 3-kinase (PI3K) inhibitor Ly294002 on collage-induced Akt phosphorylation in platelets at 50 μM[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
CAS No. 119425-89-7
-
Appearance Solid
-
분자량 286.32
-
화학식 C17H18O4
-
Color White to off-white
-
SMILES
O=C(C1=CC=C(O)C=C1)CCC2=CC=C(OC)C=C2OC
-
Structure Classification
-
Initial Source
-
선적
Room temperature in continental US; may vary elsewhere.
-
보관
Powder -20°C 3 years 4°C 2 years In solvent -80°C 2 years -20°C 1 year
Publications (6)
-
Journal Impact Factor
-
Most Recent
-
Biomed Pharmacother
Developing neobavaisoflavone nanoemulsion suppresses lung cancer progression by regulating tumor microenvironment. [Abstract]2020 Sep;129:110369. PMID: 32563983 -
Int Immunopharmacol
Downregulating Akt/NF-κB signaling and its antioxidant activity with Loureirin A for alleviating the progression of osteoarthritis: In vitro and vivo studies. [Abstract]2020 Jan;78:105953. PMID: 31784401 -
Eur J Immunol
Fibroblast transdifferentiation promotes conversion of M1 macrophages and replenishment of cardiac resident macrophages following cardiac injury in mice. [Abstract]2020 Jun;50(6):795-808. PMID: 32068249 -
Life
Targeting MAPK Signaling: Loureirins A and B from Dracaena Loureiri Inhibit Epithelial-Mesenchymal Transition and Invasion in Non-Small Cell Lung Cancer Cell Lines. [Abstract]2025 Mar 3;15(3):396. PMID: 40141741 -
Orthop Surg
2023 May;15(5):1375-1383. PMID: 37057624 -
Biol Pharm Bull
Loureirin A Promotes Cell Differentiation and Suppresses Migration and Invasion of Melanoma Cells via WNT and AKT/mTOR signaling Pathways. [Abstract]2024 Feb 22;47(2):486-498. PMID: 38199251
용액&용해도
DMSO : ≥ 86.6 mg/mL (302.46 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
* "≥" means soluble, but saturation unknown.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.08 mg/mL (7.26 mM); Clear solution
This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.08 mg/mL (7.26 mM); Clear solution
This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
순도&문서
-
Data Sheet (271 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Portuguese - PT (393 KB)
-
Handling Instructions (2659 KB)
References
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 3.4926 mL | 17.4630 mL | 34.9260 mL | 87.3149 mL |
| 5 mM | 0.6985 mL | 3.4926 mL | 6.9852 mL | 17.4630 mL | |
| 10 mM | 0.3493 mL | 1.7463 mL | 3.4926 mL | 8.7315 mL | |
| 15 mM | 0.2328 mL | 1.1642 mL | 2.3284 mL | 5.8210 mL | |
| 20 mM | 0.1746 mL | 0.8731 mL | 1.7463 mL | 4.3657 mL | |
| 25 mM | 0.1397 mL | 0.6985 mL | 1.3970 mL | 3.4926 mL | |
| 30 mM | 0.1164 mL | 0.5821 mL | 1.1642 mL | 2.9105 mL | |
| 40 mM | 0.0873 mL | 0.4366 mL | 0.8731 mL | 2.1829 mL | |
| 50 mM | 0.0699 mL | 0.3493 mL | 0.6985 mL | 1.7463 mL | |
| 60 mM | 0.0582 mL | 0.2910 mL | 0.5821 mL | 1.4552 mL | |
| 80 mM | 0.0437 mL | 0.2183 mL | 0.4366 mL | 1.0914 mL | |
| 100 mM | 0.0349 mL | 0.1746 mL | 0.3493 mL | 0.8731 mL |
Powered by Bioz